Maricel Apuli - 16 May 2026 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Chief Accounting Officer
Issuer ticker: BBIO
Reported as of: 16 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2026, 16:26:42 UTC
Prior SEC filing: 04 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Maricel Apuli

Key filing fact

Maricel Apuli filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 19 May 2026.

Key facts

This page summarizes Maricel Apuli's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2026, 16:26.

Change

Previous filing in this sequence was filed on 04 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002058197 Primary reporting owner

Apuli Maricel

Relationship: Chief Accounting Officer
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Maricel Apuli
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Tax liability

Transaction value
Shares: -4,714
Change %: -3.5%
Price: $66.13^*
Shares after: 129,401
Date: 16 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,260 shares of Common Stock underlying the Reporting Person's RSUs.